Tonix to present on PTSD med
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix), a company that is developing innovative pharmaceutical products to address public health challenges, announced today that it will present at The MicroCap Conference on April 4, 2017 in New York, NY.
Seth Lederman, M.D., president and chief executive officer of Tonix, will provide a corporate update and an overview of Tonix’s posttraumatic stress disorder (PTSD) clinical program. TNX-102 SL* was recently granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for the treatment of PTSD. This month, Tonix dosed the first patient for the “HONOR” study, a 12-week placebo-controlled Phase 3 clinical study evaluating TNX-102 SL 5.6 mg, in military-related PTSD. The interim analysis of the HONOR study is expected in the first half of 2018 and topline results are expected in the second half of 2018. Additional details of the HONOR study are available at http://www.thehonorstudy.com or https://clinicaltrials.gov/ct2/show/NCT03062540.
In his podium presentation, Dr. Lederman will also provide details of Tonix’s recently expanded therapeutic pipeline in PTSD and the new development program in a potential smallpox-preventing vaccine containing a live form of horsepox virus (HPXV).
|Event:||The MicroCap Conference|
|Date:||Tuesday, April 4, 2017|
|Time:||9:00 am ET|
|Location:||Track 1, JW Marriott Essex House, New York, NY|
The presentation will be webcast live and remain available for 90 days. To access the webcast, please visit the Events tab of the Investor Relations section of Tonix’s website at http://www.tonixpharma.com.
*TNX-102 SL (cyclobenzaprine HCl sublingual tablets) is an investigational new drug and has not been approved for any indication.